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SUMMARY:   1 
The 6th OARSI Workshop on Imaging in Osteoarthritis combined with the 3rd OA Biomarkers 2 
Workshop is the first to bring together the imaging and molecular biomarker communities to 3 
focus on clinical validation and qualification of osteoarthritis biomarkers. The workshop was 4 
held in Hilton Head, SC, USA, from June 12-14, 2012; 138 attendees participated, including 5 
representatives from academia, pharmaceutical and MRI industries, FDA, and NIH. 6 
Presentations and discussions raised awareness, consolidated knowledge, and identified 7 
strategies to overcome challenges for the development and application of imaging and 8 
biochemical biomarkers in OA research studies and clinical trials. 9 
CONCLUSIONS:  10 
The OA research communities need to work alongside regulatory agencies across the world, to 11 
qualify and validate new chemical and imaging biomarkers for future research and clinical trials. 12 
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Magnetic resonance imaging (MRI) of knee joints has contributed significantly to the change in 1 
perception of osteoarthritis (OA) from wear and tear disease limited to radiographic changes in 2 
bone and loss of joint space related to cartilage, to a multi-tissue, whole organ, complex disease 3 
with many phenotypes [1]. Aging, obesity, injuries, and an adverse mechanical environment 4 
from joint malalignment, can all contribute to OA incidence and progression. The disease may 5 
also proceed via different metabolic pathways influenced by race, genetics, and gender. 6 
OA is a symptomatic disease associated with characteristic changes in synovial tissue 7 
structures. Imaging modalities should reflect this complex phenotype. Although, MRI is a 8 
holistic structural assessment modality that provides measures that are the most direct and 9 
valid measure of joint status, and the most responsive measure of disease progression [1], the 10 
United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 11 
have yet to accept MRI as an imaging endpoint for OA in clinical trials. Currently, the 12 
quantitative measurement of radiography-based joint space width (JSW) is the only accepted 13 
imaging endpoint in disease modification efficacy OA trials. Development of disease-modifying 14 
therapy has been slowed because radiography has limited capacity to detect clinically 15 
meaningful changes in joint morphology that accompany disease progression.  16 
The utility of any disease-related biomarker is a function of how well the marker links disease 17 
biology and pathology with clinical outcomes. Pain, which along with JSW is a common 18 
endpoint in OA clinical trials, appears to at least partly derive from joint tissue alterations 19 
(including synovitis, effusion, meniscal pathology, and bone marrow lesions) but associations are 20 
generally moderate. Not only do these changes go undetected on conventional radiographs, but 21 
pain often antedates radiographic manifestations of disease (Figure 1). Moreover, the 22 
structural OA disease process and related pain are dynamic. Such variation in disease 23 
progression requires biomarkers that can reflect morphological and pathological changes in 24 
joints, beginning in the earliest stages of OA development and progression and throughout the 25 
course of disease (see Figure 1). For example, biochemical markers may reflect ultra-structural 26 
changes in joint tissue metabolism very early in the disease process prior to any apparent 27 
change in imaging appearance on either radiographs or MRI. Similarly, short-term (weeks/ 28 
months) variation in symptoms is unlikely to be reflected in poorly responsive endpoints such 29 
as radiographs. 30 
The OA biomarker community has been addressing these and other issues in a series of 31 
workshops [2]. Most recently, the OARSI Biomarkers Workshop III – Imaging Biomarker 32 
Validation and Quantification organized in conjunction with the 6th International Workshop on 33 
Osteoarthritis Imaging, was held July 12 – 14 on Hilton Head Island, South Carolina. More than 34 
138 scientists from academia, the government, and the private sector convened for the event.  35 
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Research presented at the three-day meeting highlighted progress in the field to validate MRI 1 
as a biomarker with prognostic and/or diagnostic capabilities. 2 
Meeting participants endorsed a plan to facilitate the use of MRI as an endpoint in large-scale, 3 
multi-center interventional clinical trials with extended follow-up lasting one and two years, to 4 
ascertain the efficacy and safety of different interventions using MRI-based measures as a 5 
biomarker of efficacy. In discussing the population on which to base such trials, participants 6 
agreed that such a study should, in one instance, focus on recently injured joints; this study 7 
paradigm facilitates defining a pathway to OA development and progression because the 8 
inciting event and time can be clearly identified (a summary of issues under discussion can be 9 
found in Table 1). Meeting participants also emphasized that such trials should utilize imaging 10 
technology that could detect differences in the morphological and compositional makeup of an 11 
injured joint; detect differences between the injured and uninjured joint; and monitor changes 12 
in morphological and compositional makeup over time.  13 
Identifying the appropriate imaging modality and parameters will be critical for ensuring 14 
responsive, reproducible and reliable outcomes. OA typically progresses very slowly so that the 15 
disease can remain at the same structural and clinical level of severity for many years. Without 16 
accurate MRI technology, a bone marrow lesion (BML) can be confused with a contusion or 17 
subchondral insufficiency fracture, and what looks like a meniscal tear or cartilage lesions can 18 
simply be an artifact.  19 
An MRI protocol that can assess cartilage quality (e.g. matrix composition) along with 20 
morphology and shape measures may help distinguish pathology from normal reparative 21 
processes (e.g. increase in cartilage thickness seen after ACL injury could be pathological 22 
swelling or adaptive hypertrophy) [3]. Imaging modalities that rely on intravenous contrast 23 
administration, which would be useful in assessing synovitis or cartilage proteoglycan 24 
(dGEMRIC),may be difficult to use in the current clinical trials and epidemiological studies since 25 
they add complexity to the study design and prolong the procedure time; contrast injection 26 
necessitates ascertaining adequate renal function prior to injection in order to avoid the very 27 
rare contrast medium-induced nephropathy, and entails a waiting period prior to image 28 
acquisition. 29 
Some of the main drivers in MRI research have been a pursuit of improved metrics for OA trials 30 
and their acceptance by regulatory agencies. Although quantitative measurement of cartilage 31 
thickness on MRI may have high validity, carrying it forward for trials and clinical use depends 32 
on a response from the FDA and the EMA (amongst other world-wide regulatory authorities). In 33 
2010, OARSI submitted an analysis to the FDA in which the use of MRI in osteoarthritic joints 34 
was detailed. The FDA is actively working to address recommendations necessary to approve 35 
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MRI parameters as endpoints in clinical trials and this may be facilitated by a formal request for 1 
biomarker qualification. 2 
In the opinion of some of the meeting attendees, the imaging biomarkers that may be best 3 
suited for quantitative measurement of cartilage composition on MRI assessed are T2 and 4 
potentially T1rho.  Both T2 and T1rho can be implemented and assessed using a software 5 
package that could be purchased and standardized across sites [4].  However, there are 6 
challenges regarding the reproducibility of T2 and T1rho, and thus these modalities will need to 7 
be further standardized before implementation across machines and sites.  8 
In all likelihood, any imaging modality utilized as a biomarker will be used in conjunction with 9 
biochemical measures. Towards that end, OARSI, as part of an initiative with the Foundation of 10 
NIH, has initiated a study using Osteoarthritis Initiative samples to generate data on 12 urine 11 
and serum OA biomarkers related to cartilage and bone turnover. Although there’s still a need 12 
for more specific validation regarding origin, these biochemical measures will be correlated 13 
with imaging measures (or outcomes). Urine sampling is not invasive and is particularly valuable 14 
for collagen biomarkers; but biomarker levels need to be normalized to urine creatinine to 15 
account for the varying hydration states of the individuals. This initiative will provide the 16 
opportunity to compare a large cadre of imaging and biochemical markers and to evaluate the 17 
potential synergy for these different types of markers singly, and in combination, to reflect 18 
disease status and progression.  19 
The joint itself can be viewed as a “test tube,” with the synovial fluid providing access to 20 
proximal information regarding joint tissue metabolites that can be correlated with imaging or 21 
histological outcomes. Disadvantages to synovial fluid sampling are several, including: 22 
discomfort to the patient, dislike of the procedure by practitioners, requirement for ancillary 23 
imaging (ultrasound or computed tomography) for sampling of some joints (such as the hip) 24 
and short half-life of some biomarkers in the joint (e.g. the brief half-life of hyaluronic acid in 25 
the joint suggests that the concentration of hyaluronic acid changes over minutes). Although 26 
there are disadvantages to sampling synovial fluid, in a research setting it can provide the most 27 
proximal quantitative data through biomarker analyses of the disease process and thereby can 28 
be invaluable for providing biological insights in the disease.  29 
Biochemical biomarkers may also help categorize who is at risk and who may benefit from 30 
screening for OA by helping detect signal changes linked to OA. Recognizing those patients who 31 
will progress rapidly will prove critical in the effort to accurately stage the disease and thus 32 
identify people most at risk and most likely to benefit from therapeutic intervention.  33 
There is a critical need for imaging methods to evaluate DMOAD activity in a reasonable 34 
timeframe, with reasonable sample size, at a reasonable cost. Setting a framework to evaluate 35 
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OA biomarkers that include potential for surrogacy as a major emphasis in modifiable disease 1 
pathways affecting patient outcomes will identify and advance biomarkers with the greatest 2 
promise.  3 
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 1 
Table 1. Designing the Optimal Trials for Understanding OA. Discussion and Future Directions 
Discussion Points Suggestions 
Determine imaging modalities for longitudinal 
multi-center injury trials. 
Use T2 as basis assessment of joint 
morphology and then T1rho as background if 
this modality can be standardized. 
Establish standard measurement parameters 
on imaging (a core-set).  
For example of cartilage composition, 
cartilage lesions and cartilage thickness, shape 
measures need to be collected to determine 
effect and which best predicts long term 
clinical outcome 
Determine best strategy for regulatory bodies 
to generate different guidance criteria for 
different phases of clinical trial intervention. 
Include MRI with all the other endpoints in 
early phase trials (especially Phase 2), and 
then determine if you can use it later as a 
primary endpoint based on the study.  
Modify requirement for 30-50% reduction in 
JSW as a threshold for evidence of successful 
structural modification as no single drug will 
impact readily this parameter. 
Identify which structural changes are most 
specifically associated with clinical endpoints 
in (knee) OA, and hence need to be treated.  
Reach a consensus on standardized clinical 
endpoint so studies are easier to compare.   
 
Explore utility of virtual total joint 
replacement (TJR) as a potential endpoint in 
future clinical trials.  
Determine histopathological relationship 
among structural changes to cartilage and 
subchondral bone and 'soft' tissues of the 
articular organ that can be seen on MRI. (Joint 
tissue- MRI structure correlation) 
 
Match treatable pathology with appropriate 
imaging methodology. 
 
 
Monitor patients for damage in other joints 
especially when treated by highly effective 
analgesics; any damage needs to be detected 
early. 
Some suggested methods of determining risk 
include asking patients about pain levels; 
radiographic screening; joint specific 
biochemical markers.  
Determine whether quantitative MRI, either 
morphometric, compositional or semi-
quantitative as an endpoint, is a suitable 
method to be used in cartilage repair trials 
and for long term follow up. 
 
Establish imaging criteria that will label 
cartilage repair procedures successful from a 
Need to measure local changes in 
collagen/GAG and quantitative MRI for 
morphology suitability but success of the 
intervention is determined by the long term 
outcome for the whole joint. 
 
MRI (as opposed to arthroscopy) may not be 
the most suitable outcome for assessing the 
9 | P a g e  
 
Table 1. Designing the Optimal Trials for Understanding OA. Discussion and Future Directions 
radiological and histological standpoint.  
 
boundary between native and repaired 
cartilage.  
 
Be mindful of what one considers successful, 
as it depends on the patients' expectations. 
 1 
 2 
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Figure 1. The natural history of osteoarthritis and the purported roles of biomarkers during the disease process. Original 1 
attributed to V Kraus (originally presented at OARSI Congress 2009: Kraus, VB. 2009. Clinical perspective on the role of 2 
biomarkers and the diagnosis and monitoring of OA. Osteoarthritis Cartilage Sept 17 (Suppl 1): S1.) can also be found in [5].  3 
 4 
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